Company intelligence / Profile preview
Luxna Biotech Co., Ltd.
Suita, Osaka, Japanluxnabiotech.co.jp ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Other
01
Overview
The company has developed modified bridged oligonucleotides with high affinity for targeted mRNA and reduced risk of hepatotoxicity. They have a patent granted in January 2024 for a small cell lung cancer therapeutic agent containing oligonucleotide.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Oligonucleotide therapeuticsAntisense oligonucleotides (ASO)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Servier (neurological diseases)Takeda (exclusive license for nucleic acid-based therapies)Aligos Therapeutics (targeting respiratory viruses including Coronaviridae)
Beyond the preview
Go deeper on Luxna Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Luxna Biotech Co., Ltd..